Influenza vaccination and treatment in children with neurologic disorders. (July 2014)

• Record Type: Journal Article
• Authors: Havers, Fiona; Fry, Alicia; Peacock, Georgina; Finelli, Lyn
• Is Part Of: Therapeutic advances in vaccines. Volume 2:Number 4(2014:Oct.)
• Page Start: 95
• Page End: 105
• Publication Date: 2014-07
• Subjects: Influenza -- influenza vaccination -- neurologic disorders; Vaccines -- Periodicals; 615.372
• DOI: 10.1177/2051013613519217
• Languages: English
• ISSNs: 2051-0136

Abstract

Influenza viruses cause substantial morbidity in children each year, especially among children with specific chronic conditions. In particular, neurologic disorders have emerged as a strong risk factor for influenza-related complications. Children with these disorders may be vulnerable due to diminished respiratory muscle strength, decreased muscle tone or impaired mobility, which can compromise pulmonary function and the ability to handle secretions. Although they represent a small fraction of the general pediatric population, children with neurologic disorders make up a disproportionately high number of those children who are hospitalized and die as a result of influenza-associated complications. Annual vaccination is the most effective way to prevent influenza and its complications, and is recommended for all children 6 months through 18 years of age, including children with neurologic disorders. Family members and those who work with these children in institutional, educational and daycare settings should also be vaccinated against influenza annually. However, there have been few studies of influenza vaccination specifically in this population. In addition, vaccine effectiveness may vary from year to year and vaccination will not prevent all infections. Early empiric antiviral treatment should be started promptly in these children if they present to healthcare providers with symptoms suspicious for influenza. This article reviews influenza epidemiology in children with neurologic disorders and what is known about vaccines and other methods of protecting this vulnerable population from influenza-related complications.